<DOC>
	<DOCNO>NCT01087723</DOCNO>
	<brief_summary>To show early administration bivalirudin improve 30 day outcome compare current standard care participant ST segment elevation acute coronary syndrome ( STE-ACS ) , intend primary percutaneous coronary intervention ( PCI ) management strategy , present either via ambulance center PCI perform .</brief_summary>
	<brief_title>European Ambulance Acute Coronary Syndrome ( ACS ) Angiography Trial</brief_title>
	<detailed_description>The purpose trial show early administration bivalirudin improve 30-day outcome compare current standard care participant STE-ACS , onset symptom &gt; 20 minute &lt; 12 hour , intend primary PCI management strategy , present either via ambulance center PCI perform . All participant receive treatment aspirin ( 150-325 milligram [ mg ] administer orally 250-500 mg intravenously [ IV ] ) , follow 75-100 milligrams/day ( mg/day ) least 1 year load dose approve P2Y12 receptor blocker , clopidogrel , prasugrel , ticagrelor , continue per European Society Cardiology guideline ( preferably 1 year ) participant . The primary objective trial show , compare standard anti-thrombotic therapy bivalirudin ( include treatment unfractionated heparin [ UFH ] optional glycoprotein IIb/IIIa inhibitor [ GPI ] ) 30 day : • Bivalirudin superior control reduce composite death non-coronary artery bypass graft ( CABG ) -related protocol major bleeding .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>The decision randomize participant make qualified physician paramedic present time . Participants include study present either via ambulance center PCI perform meet follow criterion : 1 . Provided write informed consent initiation study related procedure . Participants randomize ambulance may initially sign abridged version . 2 . Aged ≥18 year time randomization . 3 . Had presume diagnosis STEACS onset symptom &gt; 20 minute &lt; 12 hour one follow : ST segment elevation ≥1 millimeter ( mm ) ≥2 contiguous lead Presumably new leave bundle branch block An inferolateral myocardial infarction ST segment depression ≥1 mm ≥2 lead V13 positive terminal T wave 4 . All participant would proceed emergent angiography primary PCI indicate &lt; 2 hour first medical contact Participants exclude study follow exclusion criterion apply prior randomization : 1 . Any bleeding diathesis severe hematological disease history intracerebral mass , aneurysm , arteriovenous malformation , hemorrhagic stroke , intracranial hemorrhage , gastrointestinal genitourinary bleeding within last 2 week . 2 . Participants undergone recent surgery ( include biopsy ) within last 2 week . 3 . Participants warfarin ( applicable International Normalized Ratio know &lt; 1.5 ) . 4 . Participants receive UFH , LMWH , bivalirudin immediately randomization . 5 . Thrombolytic therapy within last 48 hour . 6 . Absolute contraindication allergy could premedicated iodinated contrast study medication include aspirin clopidogrel . 7 . Contraindications angiography , include limit severe peripheral vascular disease . 8 . If know , pregnant nursing mother . Women childbearing age ask pregnant thought may pregnant . 9 . If know , creatinine clearance &lt; 30 milliliter/minute dialysis dependent . 10 . Previous enrolment study . 11 . Treatment investigational drug device within 30 day precede randomization plan use investigational drug device trial . 12 . Participants may enrol duration randomize investigational medicinal product antithrombin infusion likely &lt; 30 minute time onset commencement angiography . 13 . Participants may enrol within primary PCIcapable hospital ( unless time randomization , catheter laboratory available , participant require transfer another primary PCI capable hospital ) . 14 . Estimated body weight &gt; 120 kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>EUROMAX</keyword>
	<keyword>STEMI</keyword>
	<keyword>STE-ACS</keyword>
	<keyword>UFH</keyword>
	<keyword>bivalirudin</keyword>
	<keyword>PCI</keyword>
	<keyword>ambulance study</keyword>
	<keyword>STE-MI participant</keyword>
</DOC>